Challenges in the discontinuation of chronic hepatitis B antiviral agents

doi:10.4254/wjh.v13.i9.1042

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5510)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

342

WORD

119

HTML

3366

Figures (1-2)

235

Tables (1-6)

549

Sum=4611

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

340

Download

559

Sum=899

Sep 27, 2021 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Sep 27, 2021; 13(9): 1042-1057
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1042

Open in New Tab Full Size Figure Download Figure

Figure 1 Advantages vs disadvantages of antiviral agent discontinuation in chronic hepatitis B. HBsAg: Hepatitis B surface antigen; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 2 Proposed ideal candidates to for stopping the use of antiviral agents in chronic hepatitis B patients. EOT: End of treatment; HBcrAg: Hepatitis B core-related antigen; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus.

Citation: Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057
URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1042.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1042